Caribou Biosciences Reports $24.3 Million Net Loss in Q2 2026, Improved from Last Year

Caribou Biosciences, Inc. reported a net loss of $24.3 million for the second quarter of 2026, a significant improvement compared to a net loss of $54.1 million in the same period last year. For the first half of 2026, the company recorded a net loss of $49.4 million, down from $94.1 million in the first half of 2025. The reduction in losses is attributed to a decrease in operating expenses, which fell to $26.8 million in the second quarter from $50.2 million a year earlier, primarily due to lower research and development costs and the absence of impairment charges that were recorded in the previous year.

Total revenue for the second quarter was $1.5 million, a decline from $2.7 million in the same quarter of 2025. This decrease was largely due to the absence of milestone payments that had been recognized in the prior year. For the first half of 2026, revenue totaled $3.9 million, down from $5.0 million in the first half of 2025. The company continues to rely on licensing and collaboration agreements for revenue generation, as it has not yet commercialized any products.

In terms of operational developments, Caribou's cash and cash equivalents increased to $26.2 million as of June 30, 2026, compared to $12.4 million at the end of 2025. The company also reported a total of $113.8 million in cash, cash equivalents, and marketable securities, which it expects will be sufficient to fund operations for at least the next 12 months. The company’s employee headcount was reduced by approximately 32% in 2025, and as of June 30, 2026, it had 105.9 million shares outstanding, reflecting an increase from 95.1 million shares at the end of 2025.

Strategically, Caribou is advancing its clinical-stage allogeneic CAR-T cell therapies, including vispacabtagene regedleucel (vispa-cel) and CB-011, which are being evaluated in ongoing clinical trials. The company has reached alignment with the FDA on the design of its pivotal phase 3 trial for vispa-cel, which is expected to enroll approximately 250 patients. The company anticipates that expenses will increase as it progresses its clinical trials and prepares for potential commercialization of its product candidates.

Looking ahead, Caribou acknowledges the ongoing need for additional capital to support its operations and clinical development efforts. The company plans to continue leveraging equity financing, licensing arrangements, and other funding sources to meet its financial needs. The successful development and commercialization of its CAR-T cell therapies remain contingent on achieving regulatory approvals and generating sufficient revenue from product sales in the future.